Mime is transforming the development of subcutaneous (SC) biologic therapies by engineering ultra-high-concentration formulations that achieve high drug loads in standard injection volumes while maintaining optimal flow properties for convenient self-administration.
This formulation technology enables well-tolerated subcutaneous injections, supports less frequent dosing, and has the potential to significantly improve treatment adherence for patients with chronic immunologic and neurologic conditions.
The platform is molecule-agnostic and works across a range of biologics, including monoclonal, bispecific, and multi-specific antibodies, Fc-fusion proteins, antibody-drug conjugates and antibody fragments. It also enables high-concentration biologics formulations for intravitreal, intrathecal delivery and other next-generation administration routes.
Our proprietary formulation platform creates ultra-high-concentration, long-acting biologics with excellent stability, bioavailability, and pharmacokinetics that are equal to or exceed best-in-class benchmarks.
This platform enables high drug loads in standard injection volumes, extended dosing intervals, superior flow properties, and significantly better subcutaneous patient experience compared with traditional intravenous infusions or frequent SC injections.
High drug loads in standard volumes with optimal flow properties.
Extended dosing intervals – quarterly or less – for patient convenience.
Excellent stability and pharmacokinetics that meet or exceed benchmarks.
Well-tolerated, self-administered injections vs. traditional IV or frequent SC.
Our product candidates are selected to support efficient and manageable development timelines by leveraging Mime's formulation capabilities and insights into disease pathways, enabling a focus on large patient populations with substantial remaining unmet need.
Mime's product candidates are engineered as fully human, ultra-high-concentration, long-acting subcutaneous biologic treatments. Each product candidate offers significant revenue potential, plus the opportunity for additional revenue expansion through follow-on indications.
Mime partners with pharmaceutical companies and biotechs to optimize their biologic therapies using our ultra-high-concentration, highly tolerable, long-acting formulation platform.
We engineer each biologic to meet defined attributes for concentration, stability, tolerability, and dosing interval — supporting subcutaneous self-administration and yielding a highly differentiated, competitively positioned, patient-friendly product profile.
The platform is molecule-agnostic across monoclonal, bispecific, and multi-specific antibodies, Fc-fusion proteins, antibody-drug conjugates and antibody fragments. It also enables high concentration biologics formulations for intravitreal, intrathecal delivery and other next-generation administration routes.
Our formulations offer potential for fresh patents that add to the commercial life of established commercial or pipeline biologics.
Complete the form below to connect with a team member and share your development goals.